French Innovative Leukemia Organisation

This study tests whether combining two drugs, ibrutinib and daratumumab, can better control relapsed or refractory chronic lymphocytic leukemia (CLL) in patients with a specific genetic problem (p53 dysfunction). About 29 adults with this high-risk form of CLL will receive both d…

This study looks at whether older, frail patients with untreated chronic lymphocytic leukemia (CLL) can safely stop taking the targeted drug acalabrutinib after 18 months and then restart it only if symptoms return. The goal is to reduce long-term side effects and the risk of dru…

This study tests whether the drug venetoclax can help people with early-stage, high-risk chronic lymphocytic leukemia (CLL). About 82 participants with specific risk factors will receive venetoclax to see if it can reduce cancer cells to very low levels in the bone marrow after 1…

This study follows 1,000 adults in France with CLL or SLL who need treatment. Researchers will observe which therapies doctors choose in everyday practice and how different treatment sequences affect survival and side effects. The goal is to learn from real-world experience, not …